SELECTIS HEALTH, INC. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a company in the midst of a high-stakes restructuring. The tension lies between the successful execution of a divestiture strategy and the fragility of the remaining core operations. While the sale of Georgia assets has provided a temporary lifeline and a significant reduction in total debt, the company has yet to prove it can generate positive cash flow from its remaining healthcare facilities without relying on one-off gains. Investors are left to weigh the benefits of a leaner, deleveraged balance sheet against the risks of a shrinking revenue base and systemic internal control failures. The upcoming finalization of the Georgia exit in May 2026 will be the definitive catalyst, determining whether the resulting liquidity is sufficient to stabilize the company or if Selectis remains trapped in a cycle of asset liquidation to service its remaining debt obligations.